Salix Pharmaceuticals, Ltd. (SLXP) Announces Statistically Significant Results for Budesonide Foam in the Treatment of Active Mild to Moderate Ulcerative Proctitis or Ulcerative Proctosigmoiditis in Two Pivotal Phase 3 Studies
5/22/2013 11:08:44 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) Outlines Data Presentations at Digestive Disease Week 2013
5/17/2013 7:33:01 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) Reports 1Q2013 Results
5/10/2013 7:51:30 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) Announces 1Q2013 Financial Results Conference Call and Webcast
4/25/2013 8:57:16 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) Commits $1.125M to AGA Research Foundation
3/13/2013 10:13:43 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) Reports 4Q2012 and FY2012 Results
3/1/2013 7:20:09 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) to Present at Two Investment Conferences in March
2/26/2013 6:53:36 AM
More...
|
FDA Approves Salix Pharmaceuticals, Ltd. (SLXP)'s Diarrhea Drug for HIV/AIDS Patients
1/2/2013 6:25:37 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) to Present at J.P. Morgan Healthcare Conference
1/2/2013 6:20:31 AM
More...
|
Salix Pharmaceuticals, Ltd. (SLXP) Donates $500,000 to ASGE's IT&T Capital Campaign to Build a New State-of-the-Art GI Training Center
12/6/2012 5:56:25 AM
More...
|
|